FDA-cleared profile

ABMD Software

HeartLung Corporation · CT/CTA · FDA-cleared (510(k))

Authorized purpose: The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.

Clinical role
Post-processing and opportunistic BMD measurement from existing CT.
Images and patients
CT/CTA · Trabecular vertebral bone and lumbar spine
Key limitation
Keep in mind: The FDA labeling states that the module is not a replacement for DXA or another dedicated BMD examination. Results are opportunistic CT measurements and require review of scan quality, calibration, anatomy, and clinical context.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Trabecular vertebral bone and lumbar spine Input: Existing CT DICOM studies with acquisition metadata and patient age and sex.
  • Who uses it?Intended users: Radiologists and healthcare providers who review CT-derived bone-mineral-density information.
  • What does the software produce?Output: Vertebral segmentation, trabecular Hounsfield-unit measurements, calculated BMD, Z and T scores, snapshots, and measurements for human review.
  • What is its most important limitation?Key limitation: The FDA labeling states that the module is not a replacement for DXA or another dedicated BMD examination. Results are opportunistic CT measurements and require review of scan quality, calibration, anatomy, and clinical context.

Clinical takeaway. Clinical role: The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation testing and two performance studies: Study 1 used 993 quantitative CT (QCT) readings of asymptomatic cases, and Study 2 used 172 asymptomatic cases who underwent whole-body DXA and CT scans. ABMD Software correlated with manual QCT-based BMD measurement (r = 0.97, p<0.01) and with DXA BMD measurement (r = 0.72, p<0.01). Clinical testing was not required. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Post-processing and opportunistic BMD measurement from existing CT.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Existing CT DICOM studies with acquisition metadata and patient age and sex.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Vertebral segmentation, trabecular Hounsfield-unit measurements, calculated BMD, Z and T scores, snapshots, and measurements for human review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical CT and radiology workflows, including opportunistic assessment during another CT procedure.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists and healthcare providers who review CT-derived bone-mineral-density information.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling states that the module is not a replacement for DXA or another dedicated BMD examination. Results are opportunistic CT measurements and require review of scan quality, calibration, anatomy, and clinical context.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification and validation testing and two performance studies: Study 1 used 993 quantitative CT (QCT) readings of asymptomatic cases, and Study 2 used 172 asymptomatic cases who underwent whole-body DXA and CT scans. ABMD Software correlated with manual QCT-based BMD measurement (r = 0.97, p<0.01) and with DXA BMD measurement (r = 0.72, p<0.01). Clinical testing was not required. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Study 1 Study 2 Reference 993 quantitative CT (QCT) readings of a 172 asymptomatic cases who underwent Dataset cohort of asymptomatic cases who whole-body DXA scans as well as CT underwent CT scans. scans.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification and validation testing and two performance studies: Study 1 used 993 quantitative CT (QCT) readings of asymptomatic cases, and Study 2 used 172 asymptomatic cases who underwent whole-body DXA and CT scans. ABMD Software correlated with manual QCT-based BMD measurement (r = 0.97, p<0.01) and with DXA BMD measurement (r = 0.72, p<0.01). Clinical testing was not required. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Study 1 Study 2 Reference 993 quantitative CT (QCT) readings of a 172 asymptomatic cases who underwent Dataset cohort of asymptomatic cases who whole-body DXA scans as well as CT underwent CT scans. scans.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K213760 FDA evidence package for ABMD Software

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationTrabecular vertebral bone and lumbar spine
  • Scopeexact submission
  • Tested versionAutomated Bone Mineral Density Software Module
  • IndependenceSponsor or vendor study

K213760

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K213760 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Existing CT DICOM studies with acquisition metadata and patient age and sex.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K213760: ABMD Software

  2. Routing

    Source context, not route validation: The FDA package describes existing CT DICOM input, metadata extraction, vertebral segmentation, and exported snapshots and measurements.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K213760: ABMD Software

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Vertebral segmentation, trabecular Hounsfield-unit measurements, calculated BMD, Z and T scores, snapshots, and measurements for human review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K213760: ABMD Software

  5. Viewer/worklist/report

    Unresolved route: Vertebral segmentation, trabecular Hounsfield-unit measurements, calculated BMD, Z and T scores, snapshots, and measurements for human review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K213760: ABMD Software

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA package describes existing CT DICOM input, metadata extraction, vertebral segmentation, and exported snapshots and measurements.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by radiologists and healthcare providers who review ct-derived bone-mineral-density information. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K213760.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K213760.

exact submission · checked 2026-09-04

Deployment boundary

The exact public deployment boundary is incomplete; confirm hosting, data flow, availability, upgrades, security, service, and downtime locally.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes existing CT DICOM input, metadata extraction, vertebral segmentation, and exported snapshots and measurements.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K213760.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K213760
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Trabecular vertebral bone and lumbar spine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-07-29
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. The records concern generic bone-mineral-density topics or the unrelated Abiomed brand and do not identify the HeartLung ABMD software, tested version, or K213760. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K213760: ABMD Software

    U.S. Food and Drug Administration - Published 2022-07-29 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ABMD Software model card (K213760)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K213760 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.

Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Decision
2026-06-11
FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K252103

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software provides modular image processing, visualization, segmentation, measurement, treatment planning, and three-dimensional-printing support; Acorn Trajectory Automation plans pedicle-screw trajectories in adult and pediatric thoracic and lumbar spine cases.

Modality
CT/CTA
Anatomy
Thoracic and lumbar spine, musculoskeletal, craniomaxillofacial, and vascular anatomy
Decision
2025-12-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history